Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))

Myrthe J. van Dijk; Jonathan R.A. de Wilde; Marije Bartels; Kevin H.M. Kuo; Andreas Glenthøj; Minke A.E. Rab; Eduard J. van Beers; Richard van Wijk

doi:10.1016/j.blre.2023.101160

Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))

Myrthe J. van Dijk, Jonathan R.A. de Wilde, Marije Bartels, Kevin H.M. Kuo, Andreas Glenthøj, Minke A.E. Rab, Eduard J. van Beers, Richard van Wijk^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Downloads (Pure)

Abstract

The authors regret that in the published article, a part of Table 2 titled ‘Main clinical study results of subjects treated with PK activators in hereditary hemolytic anemia’ was missing. A correction has therefore been made to Table 2 with the addition of the last three columns and some abbreviations in the legend. The original article has been updated. The authors would like to apologise for any inconvenience caused.

Original language	English
Article number	101160
Number of pages	1
Journal	Blood Reviews
Volume	64
Early online date	2 Dec 2023
DOIs	https://doi.org/10.1016/j.blre.2023.101160
Publication status	Published - Mar 2024

Access to Document

10.1016/j.blre.2023.101160

1-s2.0-S0268960X23001303-mainFinal published version, 284 KB

Fingerprint

Dive into the research topics of 'Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))'. Together they form a unique fingerprint.

1 Review article

Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme
van Dijk, M. J., de Wilde, J. R. A., Bartels, M., Kuo, K. H. M., Glenthøj, A., Rab, M. A. E., van Beers, E. J. & van Wijk, R., Sept 2023, In: Blood Reviews. 61, 101103.
Research output: Contribution to journal › Review article › peer-review

Open Access
File
5 Downloads (Pure)

Cite this

van Dijk, M. J., de Wilde, J. R. A., Bartels, M., Kuo, K. H. M., Glenthøj, A., Rab, M. A. E., van Beers, E. J., & van Wijk, R. (2024). Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103)). Blood Reviews, 64, Article 101160. https://doi.org/10.1016/j.blre.2023.101160

@article{7be7ec51ddfe497ca1be6fdf8577cb7e,

title = "Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))",

abstract = "The authors regret that in the published article, a part of Table 2 titled {\textquoteleft}Main clinical study results of subjects treated with PK activators in hereditary hemolytic anemia{\textquoteright} was missing. A correction has therefore been made to Table 2 with the addition of the last three columns and some abbreviations in the legend. The original article has been updated. The authors would like to apologise for any inconvenience caused.",

author = "{van Dijk}, {Myrthe J.} and {de Wilde}, {Jonathan R.A.} and Marije Bartels and Kuo, {Kevin H.M.} and Andreas Glenth{\o}j and Rab, {Minke A.E.} and {van Beers}, {Eduard J.} and {van Wijk}, Richard",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2024",

month = mar,

doi = "10.1016/j.blre.2023.101160",

language = "English",

volume = "64",

journal = "Blood Reviews",

issn = "0268-960X",

publisher = "Churchill Livingstone",

}

van Dijk, MJ , de Wilde, JRA , Bartels, M, Kuo, KHM, Glenthøj, A, Rab, MAE , van Beers, EJ & van Wijk, R 2024, 'Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))', Blood Reviews, vol. 64, 101160. https://doi.org/10.1016/j.blre.2023.101160

Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103)). / van Dijk, Myrthe J.; de Wilde, Jonathan R.A.; Bartels, Marije et al.
In: Blood Reviews, Vol. 64, 101160, 03.2024.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias

T2 - Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))

AU - van Dijk, Myrthe J.

AU - de Wilde, Jonathan R.A.

AU - Bartels, Marije

AU - Kuo, Kevin H.M.

AU - Glenthøj, Andreas

AU - Rab, Minke A.E.

AU - van Beers, Eduard J.

AU - van Wijk, Richard

PY - 2024/3

Y1 - 2024/3

N2 - The authors regret that in the published article, a part of Table 2 titled ‘Main clinical study results of subjects treated with PK activators in hereditary hemolytic anemia’ was missing. A correction has therefore been made to Table 2 with the addition of the last three columns and some abbreviations in the legend. The original article has been updated. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that in the published article, a part of Table 2 titled ‘Main clinical study results of subjects treated with PK activators in hereditary hemolytic anemia’ was missing. A correction has therefore been made to Table 2 with the addition of the last three columns and some abbreviations in the legend. The original article has been updated. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85178613629&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2023.101160

DO - 10.1016/j.blre.2023.101160

M3 - Comment/Letter to the editor

C2 - 38044254

SN - 0268-960X

VL - 64

JO - Blood Reviews

JF - Blood Reviews

M1 - 101160

ER -

van Dijk MJ , de Wilde JRA , Bartels M, Kuo KHM, Glenthøj A, Rab MAE et al. Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103)). Blood Reviews. 2024 Mar;64:101160. Epub 2023 Dec 2. doi: 10.1016/j.blre.2023.101160

Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))

Abstract

Access to Document

Other files and links

Fingerprint

Research output

Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme

Cite this